How do you approach treating a patient with IgM-AL amyloidosis?  

Given the rarity of this diagnosis (5-7% of all AL amyloidosis cases), and the prognostic and clinical differences when compared to non IgM-AL amyloidosis, does your therapeutic approach differ between these groups?

Are treatment strategies for Waldenström macroglobulinemia applicable to IgM-AL amyloidosis?

Does the presence of an underlying lymphoplasmacytic lymphoma (LPL) or MYD88 mutation affect your choice of treatment?



Answer from: Medical Oncologist at Academic Institution